Federal Reserve's Voice: Powell Stays, No Rate Cuts, Walsh Faces Dilemma
On April 30, Nick Timiraos, the chief economics reporter for The Wall Street Journal in Washington and known as the 'voice of the Federal Reserve,' published an article discussing the latest Federal Reserve meeting. He pointed out that uncertainties surrounding interest rate direction and power transition are emerging simultaneously. On Wednesday, Federal Reserve Chairman Powell clearly stated at a press conference that he would not resign immediately and would continue to serve as a governor after completing the transition of the chairmanship next month. This decision breaks the tradition of the past 75 years, where previous chairmen completely left the central bank upon the arrival of their successors. At the same time, several Federal Reserve officials have sent a consistent signal: there will be no rate cuts in the short term. Three of Powell's colleagues publicly disagreed with the wording of policy communication, opposing the continued implication that the likelihood of rate cuts is higher than that of rate hikes. Cleveland Fed President Mester, Minneapolis Fed President Kashkari, and Dallas Fed President Logan indicated through this stance that, in the context of rising energy prices, core inflation remaining around 3%, and the ongoing effects of tariffs, it is difficult for monetary policy to shift towards easing. Timiraos noted that incoming Chairman Kevin Walsh thus faces a dual constraint: on one hand, the White House hopes to see rate cuts; on the other hand, a more hawkish consensus is emerging within the Federal Open Market Committee.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
